Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975698 · ClinicalTrials.gov registry record · Phase 2
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903
A Phase 2 study of HIV Associated Lymphoma, sponsored by Catherine Bollard.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 11
- Study locations
NCT04975698: Active Phase 2 study of HIV Associated Lymphoma, sponsored by Catherine Bollard.
NCT04975698 is a Phase 2 study of HIV Associated Lymphoma that is active but no longer recruiting, run by Catherine Bollard. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04975698, a Phase 2 study of HIV Associated Lymphoma, is active but no longer recruiting, sponsored by Catherine Bollard.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT) followed by administration of HST-NEETs for treatment of HIV associated lymphoma
Primary Outcome
Feasibility is defined as a participant receiving HST-NEETs within 1 week post-ASCT; Efficacy will be measured by the reduction in intact proviral reservoir.
Conditions Studied
Interventions
- BIOLOGICAL HST-NEETs
- BIOLOGICAL Bone Marrow Transplant
Study Locations (11)
New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering (MSKCC) - New York
Texas
- Baylor College of Medicine - Houston
- MD Anderson - Houston
California
- City of Hope National Medical Center - Duarte
District of Columbia
- Georgetown - Washington D.C.
Florida
- H. Lee Moffitt Cancer Center - Tampa
Georgia
- Northside - Atlanta
Illinois
- University of Illinois - Chicago
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-10-25 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT04975698 still lists
NCT04975698 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with HIV Associated Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which HST-NEETs is the first listed.
NCT04975698 lists 11 locations in 9 states (New York, Texas, California).
Frequently Asked Questions
What is clinical trial NCT04975698 about?
NCT04975698 is a clinical study titled "HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903". This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT) followed by administration of HST-NEETs for treatment of HIV associated lymphoma
What is the current status of trial NCT04975698?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-10-25. Estimated completion is 2026-06.
What conditions does trial NCT04975698 study?
This clinical trial studies the following conditions: HIV Associated Lymphoma.
What interventions are being tested in trial NCT04975698?
The interventions under investigation include: HST-NEETs (BIOLOGICAL), Bone Marrow Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT04975698?
This trial is sponsored by Catherine Bollard, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04975698 being conducted?
This trial has 11 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04975698's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI